Tocilizumab: Difference between revisions
No edit summary |
|||
| Line 7: | Line 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[COVID]]=== | ===[[COVID]]=== | ||
*8 mg/kg actual body weight (up to 800 mg) administered as a single IV dose | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 46: | Line 47: | ||
==Comments== | ==Comments== | ||
*Trials show that may improved survival and other clinical outcomes in patients in admitted severe disease | *Trials show that may improved survival and other clinical outcomes in patients in admitted severe disease | ||
*In clinical trials, a third of the participants received a second dose of tocilizumab 8 hours after the first dose if no clinical improvement was observed. | |||
==See Also== | ==See Also== | ||
Latest revision as of 21:03, 18 January 2022
Administration
- Type: IL-6 antagonist
- Dosage Forms:
- Routes of Administration:
- Common Trade Names:
Adult Dosing
COVID
- 8 mg/kg actual body weight (up to 800 mg) administered as a single IV dose
Pediatric Dosing
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
- Trials show that may improved survival and other clinical outcomes in patients in admitted severe disease
- In clinical trials, a third of the participants received a second dose of tocilizumab 8 hours after the first dose if no clinical improvement was observed.